ArticleBiological research2026
Substitution of the SEMA3A basic domain with the VEGF
Article in Biological research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAngiogenesis plays a critical role in tumor development, with neuropilin receptors (NRPs) involved in this process through their interactions with vascular endothelial growth factor (VEGF) and semaphorins. SEMA3A, a member of class 3 semaphorins, demonstrates strong antiangiogenic potential. In this study, the C-terminal basic domain of SEMA3A was replaced with the heparin-binding domain (HBD) of VEGF165, hypothesizing that the resultant chimeric protein SEMA-PSI-IG-HBD would enhance antiangiogenic efficacy by: (1) competing with VEGF for NRPs (2) utilizing the HBD as a molecular anchor to increase the residence time and local concentration of the hybrid within the tumor microenvironment.
methodsTo assess the effects of SEMA-PSI-IG-HBD on angiogenesis, a series of in vitro assays including microcapillary network formation, 3D cell spheroid sprouting, proliferation and interaction with NRP1 were carried out, whereas in ovo experiments were performed by using the chicken embryo chorioallantoic membrane (CAM) model.
resultsPull-down assays confirmed that the SEMA-PSI-IG-HBD hybrid specifically interacted with secreted NRP1 in a manner similar to the wild-type SEMA3A, validating the structural integrity of the chimeric protein’s receptor-binding interface. SEMA-PSI-IG-HBD and SEMA3A showed comparable inhibition in 2D microcapillary formation and 3D spheroid sprouting assays. However, the hybrid demonstrated markedly superior anti-angiogenic activity in the complex 3D environment of the CAM model.
conclusionsOur findings demonstrate that by combining competitive occupancy of NRP1 with potent anti-angiogenic signaling, SEMA-PSI-IG-HBD represents a promising therapeutic candidate for the regulation of pathological vascularization in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.